94/505/EC: Commission Decision of 18 July 1994 amending the… Article 1

Article 1

A favourable decision is hereby taken, according to which, the product Nobi-Porvac Aujeszky live, containing a genetically modified pseudorabies virus (strain Begonia) (gI , tk ) in a preparation with Diluvac Forte, modified by Vemie Veterinaer Chemie GmbH (Ref. C/D/92/I-1) and for which consent has been given by a Commission Decision of 18 December 1992 for the placing on the market as a live vaccine for Aujeszky disease to be administered by intra-muscular application only, shall now also be given consent for intra-dermal application as well.